Level Zero Health: Revolutionising Hormone Monitoring with Real-Time Biosensors
UK & USA heath tech business secure a record-breaking £5.5M pre-seed funding round, the largest ever secured by female founders in Europe.
Founders & Mission
Level Zero Health (LZH), co-founded by Ula Rustamova (CEO) and Irene Jia (CTO), is pioneering continuous hormone monitoring through its DNA-based biosensor platform. The company aims to replace outdated, infrequent blood tests with real-time, non-invasive tracking, addressing critical gaps in IVF treatments, testosterone deficiency, and broader hormone-related healthcare.
Breakthrough Technology
LZH’s biosensors, using interstitial fluid, provide continuous and highly accurate hormone tracking (98% clinical accuracy), surpassing existing urine- and blood-based methods. This marks a significant advancement in personalised health diagnostics.
Market Impact & Early Success
- IVF market ($25.3B in 2023) could benefit from reduced reliance on frequent blood tests.
- Testosterone deficiency (affecting 10-40% of men) could see improved patient management.
- Broader continuous biosensing market projected to exceed $20.2B by 2032.
- LZH has secured $3M in Letters of Intent (LOIs) from IVF clinics and filed a patent in 2024.
Funding & Future Plans
LZH recently raised £5.5M ($6.9M) in pre-seed funding, led by Redalpine. The funds will support FDA & CE-mark approvals, expand R&D, and scale hiring in the UK and US, paving the way for commercialisation.
Redalpine’s Philip Kneis highlighted LZH’s potential: “Continuous hormone measurement is one of the holy grails of diagnostics… paving the way for a new era of personalised health management.”
She Makes Her Features & other stories are written by She Makes Her Staff. Opinions Expressed by She Makes Her Contributors are their own